share_log

中基長壽科學：自願公告成立合資公司

ZHONG JI LS: VOLUNTARY ANNOUNCEMENTFORMATION OF A JOINT VENTURE

Hong Kong Stock Exchange ·  Apr 18 20:17
Summary by Futu AI
中基長壽科學集團有限公司（「中基長壽」）於2024年4月18日宣布，其全資附屬公司深圳市中基健康科學有限公司及間接非全資附屬公司四川中基冠德生物科技有限公司與四川中農雲起航數據科技集團有限公司簽訂合資協議，計劃在中國成立一家合資公司。該合資公司將由中基冠德擁有51%股權，中基健康擁有25%股權，中農雲擁有24%股權。新公司將專注於開發高血壓、糖尿病臨床管控的新微創技術、間質技術及相關生物製品貿易。中基長壽表示，此舉符合集團業務發展策略，有助於擴大業務範圍至生物科技技術，並為集團帶來新的收入來源。
中基長壽科學集團有限公司（「中基長壽」）於2024年4月18日宣布，其全資附屬公司深圳市中基健康科學有限公司及間接非全資附屬公司四川中基冠德生物科技有限公司與四川中農雲起航數據科技集團有限公司簽訂合資協議，計劃在中國成立一家合資公司。該合資公司將由中基冠德擁有51%股權，中基健康擁有25%股權，中農雲擁有24%股權。新公司將專注於開發高血壓、糖尿病臨床管控的新微創技術、間質技術及相關生物製品貿易。中基長壽表示，此舉符合集團業務發展策略，有助於擴大業務範圍至生物科技技術，並為集團帶來新的收入來源。
Zhongqi Longevity Science Group Co., Ltd. (“Zhongkei Longevity”) announced on April 18, 2024 that its wholly-owned subsidiary Shenzhen Zhongqi Health Science Co., Ltd., and its indirect non-wholly owned subsidiary Sichuan Zhongqi Guande Biotechnology Co., Ltd., have signed a joint venture with Sichuan Chung Nongyuan Navigation Data Technology Group Co., Ltd. Funding agreement to set up a joint venture company in China. The joint venture will be owned by CIC Kwun Tak with 51% of the shares, China-based Health with a 25% stake, and CNG will have a 24% shareholding. The new company will focus on the development of new micro-innovative technologies for the clinical control of hypertension, diabetes, intermediate technologies and related bioproducts trade. SME said the move was in line with the Group's business development strategy, helping to expand its business reach into biotechnology and bring new revenue streams to the Group.
Zhongqi Longevity Science Group Co., Ltd. (“Zhongkei Longevity”) announced on April 18, 2024 that its wholly-owned subsidiary Shenzhen Zhongqi Health Science Co., Ltd., and its indirect non-wholly owned subsidiary Sichuan Zhongqi Guande Biotechnology Co., Ltd., have signed a joint venture with Sichuan Chung Nongyuan Navigation Data Technology Group Co., Ltd. Funding agreement to set up a joint venture company in China. The joint venture will be owned by CIC Kwun Tak with 51% of the shares, China-based Health with a 25% stake, and CNG will have a 24% shareholding. The new company will focus on the development of new micro-innovative technologies for the clinical control of hypertension, diabetes, intermediate technologies and related bioproducts trade. SME said the move was in line with the Group's business development strategy, helping to expand its business reach into biotechnology and bring new revenue streams to the Group.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.